In a new study conducted in the field of unsafe medications has warned that the blood pressure curing drug Tekturna needs to be avoided in the patients who are suffering from diseases like type 2 diabetes, heart and kidney. The study has revealed that the mentioned drug has higher rates of serious adverse events associated with it as compared to other combinations of drugs. The study has clearly warned various stakeholders that the hypertensive drug shouldn’t be combined with other similar drugs in patients with renal problems, cardiovascular diseases and those suffering from Type 2 diabetes.

The study was published by the New England Journal of Medicine (NEJM) on Saturday. According to the report around 8,561 patients who were suffering from diseases like type 2 diabetes or had either kidney or cardiovascular problems were included and examined. The trial was a double-blind randomized trial in which participants were randomly assigned to take either 300 mg of Tekturna (aliskiren) or a placebo with an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB). After a close follow-up of 32 months around 18.3% of those patients experienced events like cardiovascular death, death attributable to kidney failure or occurrence of cardiac arrest. The patients who received Tekturna were also reported with events and incidences like (high potassium) and hypotension (low blood pressure) and low blood pressure.

About Tekturna:

Tekturna is a prescription drug manufactured by the pharmaceutical giant Novartis intended to treat the condition of high blood pressure. However, due to its possible links with some serious side effects and complications the drug had been under the scrutiny of FDA. It was approved by the FDA in the year of 2007 and since then it is being widely used in the United States. However, if you suffered Tekturna side effects like kidney problem or stroke the victim is eligible to file a Tekturna lawsuit and seek compensation for the physical and mental damages that he/she has suffered.

Some of the side effects that the drug is associated with are:

  • Kidney or renal complications
  • Non-fatal strokes
  • Hyperkalemia (high levels of potassium)
  • Hypotension (low blood pressure)
  • Angiodema
  • Strokes
  • Heart attacks
  • Acute renal failure
  • Syncope

Novartis launched a clinical trial called as “ALTITUDE” in an attempt to expand the market share of the drug Tekturna. The primary end-points of the trial were to determine if the drug could also be used to treat various complications pertaining to heart and kidney in patients who consume it for longer period. The study was a double-blind, placebo controlled, randomized and multi-national trial. However, Novartis halted the trial after the initial report suggested that it caused many health concerns to these key organs. Viewing the growing number of medication lawsuits pertaining to Tekturna the U.S. Food and Drug Administration warned against using Tekturna in combination with ACE inhibitors or ARBs.